I21 I61 I63 N17 H34.1 G45.0 G45.1 G45.2 G45.3 G45.9 I11.0 I13.0 I13.2 I13.9 I42 I50.13 I50.14 I50.19 I50.9 I10.0 I10.1 I10.9 E78.0 E78.1 E78.2 E78.5 I70.2 I70.8 I25.1 N18.3 N18.4 N18.5 H35.0 H36.0 G63.2
Conditions
Interventions
Group 1: Patients with acute myocardial infarction, after acute decompensated heart failure, after acute stroke, or without acute avent but with comparable high cradiovascular risk will be followed up
Sponsors
Charité Campus Charité Mitte
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) provision of signed and dated informed consent form 2) declared willingness to take part in study procedures and to be contacted again for further follow-up examinations 3) persons of any sex and gender, aged 18 years or above at the time of acute event or study inclusion 4) general health status is acceptable for participation in a study 5) recent diagnosis of one or more of the following diseases: a) acute heart failure (trigger event) b) acute coronary syndrome (trigger event) c) acute cerebrovascular disorders (trigger event) d) acute kidney injury (trigger event) 6) eligibility for the reference group, that is presence of a chronic vascular high-risk condition according to ESC-guidelines for lipid disorders 2020 and cardiovascular disease prevention 2021
Exclusion criteria
Exclusion criteria: 1. lack of capacity to give informed consent 2. Pregnancy or lactation 3. Life expectancy 24hrs who had an MRI in the acute phase, that did neither show fresh infarction (based on DWI-criteria) nor fresh hemorrhage shall not be included 8. Acute heart failure arm: AHF in the context of a hospitalization for acute coronary syndrome, acute stroke, or acute kidney injury 9. Chronic high-risk arm a history of an acute trigger event as defined by the inclusion criteria within the last 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| composite endpoint consisting of major adverse events (MACE) that occut for the first time since study inclusion: cardiovascular mortality, non-lethal stroke, non-fatal myocardial infarction and rehospitalization due to cardiac insufficiency | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. All cause mortality 2. MACE • recurrent/secondary MACE events • burden of all MACE events per pt 3. Cardiovascular events • hospitalization for unstable angina pectoris • coronary revascularization 4. Cerebrovascular events • TIA • Subarachnoid hemorrhage (SAH) • Carotid artery stenting or TEA • PFO closure • clipping or resection of a intracranial aneurysm 5. Peripheral vascular events • amputation due to PAD • revascularization of peripheral arteries • pulmonary artery embolism • diabetic end-organ damage (micronagiopathy) 6. Major adverse kidney event, MAKE 7. Every acute kidney injury | — |
Countries
Germany
Contacts
Public ContactKathrarina Schönrath
Berlin Institute of Health (BIH)
Outcome results
None listed